Patent Assignment
Reel/Frame 048383/0577
Change of Name
Recorded: 2019-02-20
Pages: 2
Assignor
QLT INC.
Executed: 2016-11-29
Assignee
NOVELION THERAPEUTICS INC.
887 GREAT NORTHERN WAY, VANCOUVER, V5T 4T5, CANADA
Covered Properties
(3)
Pharmaceutical Formulations Comprising 9-Cis-Retinyl Esters in a Lipid Vehicle
Therapeutic Regimen and Methods for Treating or Ameliorating Visual Disorders Associated with an Endogenous Retinoid Deficiency
Application:
15/968,358 →
Publication:
US 2019/0029986
Therapeutic Regimens and Methods for Improving Visual Function in Visual Disorders Associated with an Endogenous Retinoid Deficiency
Related Assignments
(7)
Other recorded transfers of the patents in this record — the chain of ownership.
Assignment of Assignor's Interest
Feb 20, 2019
From: BOCH, RONALD ERWIN
To: QLT INC.
Reel/Frame 048383/0260 →
Assignment of Assignor's Interest
Feb 20, 2019
From: CADDEN, SUZANNE
To: QLT INC.
Reel/Frame 048383/0469 →
Assignment of Assignor's Interest
Feb 20, 2019
From: STRONG, H. ANDREW; CADDEN, SUZANNE
To: QLT INC.
Reel/Frame 048383/0396 →
Assignment of Assignor's Interest
Feb 21, 2019
From: NOVELION THERAPEUTICS INC.
To: RETINAGENIX, LLC
Reel/Frame 048403/0004 →
Assignment of Assignor's Interest
Mar 20, 2020
From: RETINAGENIX, LLC
To: RETINAGENIX THERAPEUTICS, INC.
Reel/Frame 052175/0176 →
Assignment of Assignor's Interest
Apr 7, 2021
From: RETINAGENIX THERAPEUTICS, INC.
To: RETINAGENIX HOLDINGS LLC
Reel/Frame 055857/0001 →
Assignment of Assignor's Interest
Aug 9, 2022
From: RETINAGENIX HOLDINGS LLC
To: ELUMINEX BIOSCIENCES (SUZHOU) LIMITED
Reel/Frame 060763/0001 →